At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
PF-05221304drug
Likely dose
PF-05221304 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL COHORT STUDY TO COMPARE THE PHARMACOKINETICS OF PF-05221304 IN ADULT SUBJECTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO SUBJECTS WITHOUT HEPATIC IMPAIRMENT
In Brief
A Phase 1 clinical trial evaluating PF-05221304 for Hepatic Impairment. Completed, enrolled 24 participants across 6 sites in 4 countries.
Detailed Summary
Hepatic impairment PK study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment
CountriesBelgium, Czechia, Slovakia, United States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartDec 2017
Primary CompletionJun 2018
Study CompletionJul 2018
TodayJul 2026
First PostedOct 13, 2017
Enrollment StartDec 19, 2017
Primary CompletionJun 26, 2018
Study CompletionJul 18, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.7 years ago
Interventions
PF-05221304drug
25 mg dose